Navigation Links
Genomma Lab International Announces Second Quarter 2009 Results
Date:7/23/2009

l decades.

(1) EBITDA is calculated by adding pre-operative expenses, depreciation and amortization to the operating income.

(2) Earnings per share are for the last 12 months and were calculated using the weighted average number of shares outstanding for the period.

(3) As defined later in the document.

(4) As defined later in the document.

(5) As defined later in the document.

Comments from the Chairman and CEO

Mr. Rodrigo Herrera, Chairman of the Board and Chief Executive Officer, stated: "We are pleased to report our second quarter 2009 results, which showed a sound growth. We are currently experiencing a challenging economic environment, which has made difficult the Global Economy's performance; therefore, we will continue to proceed with caution. We were, once again, pleasantly surprised by the net sales level registered during this quarter; which proves that both the Company's business model, as well as its advertising strategies, continue to be successful. We expect to continue in this manner so as to continue gaining market share, increasing net sales and profitability, and thus, creating value for our shareholders.

During the second quarter of 2009, we acquired several brands, some of them are expected to strengthen our presence in certain categories, whereas others will allow us to enter new categories. We continue analyzing new initiatives, and remain committed to the growth-by-acquisitions strategy established in our Initial Public Offering. We believe that adverse economic conditions can contribute to finding attractive expansion opportunities for the Company."

For the complete version of this earnings report, please visit: www.genommalab.com

Company Description

Genomma Lab Int
'/>"/>

SOURCE Genomma Lab Internacional, S.A.B. de C.V.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Webcast Alert: Genomma Lab Internacional, S.A.B. de C.V. Announces Second Quarter 2009 Results Conference Call
2. Genomma Lab Internacional Acquires Brands Flor de Naranja Sanborns(MR), Teatrical and Henna Egipcia From Grupo Sanborns
3. Genomma Lab Internacional Announces First Quarter 2009 Results
4. Genomma Lab Acquires the Mexican Company Medicinas y Medicamentos Nacionales
5. Genomma Lab Internacional Announces Fourth Quarter and Full Year 2008 Results
6. Webcast Alert: Genomma Lab Announces Fourth Quarter 2008 Earnings Webcast
7. Genomma Lab Announces Updated Fourth Quarter 2008 Guidance
8. Genomma Lab, New Participant in Market-Maker Program
9. Genomma Lab Announces Initiation of Stock Repurchase Fund
10. Genomma Lab Announces the Successful Launch of the Ma Evans Brand
11. Genomma Lab Announces 2009 Earnings Guidance

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009).... 20 Following a recall by Unileve...from sale Shedd,s Country Crock ® Side Dishes...Crock ® Side Dishes DELUXE Four Cheese Pasta ...following code dates and UPCs are affected: ,, ...heddar Broccoli Rice 21 oz, UPC 027400218316, Best...
(Date:11/20/2009)...PRNewswire-USNewswire/ -- The American Dental Asso...dministration (FDA) to establish appropriate class...iting concern about the safety of whitening produc... of professional consultation or examination by a ... of chemically based tooth whitening or bleaching ...
(Date:11/20/2009)...., Nov. 20 Samuel Gladd...ine what it means to be "happy" during the holiday...cialty in family counseling and chair of the Depar...dding says research shows that it is the pressure ...epression during the holidays. ,, That,s why he...
(Date:11/20/2009)...ne November 20 in the Journal of the National Can... hopes that often appear in news coverage of cance...th the media and journals to help alleviate the pr...n Woloshin, M.D., M.S., of Center for Medicine and...olicy and Clinical Practice in New Hampshire, and ...
(Date:11/20/2009)...ber 20, 2009Emergency medical service (EMS) provid...00 cardiac arrests each year. Only 5 to 10 percen.... Better quality cardiopulmonary resuscitation (C...ssociated with better patient outcome. The Resusc...linical research network to study prehospital trea...
Breaking Medicine News(10 mins):Health News:Stop & Shop Alerts Customers to Voluntary Recall by Unilever 2Health News:American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products 2Health News:Why Holidays Don't Have To Be 'Happy' 2Health News:Promoting healthy skepticism in the news: Helping journalists get it right 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 3
...ch 5 Peregrine Pharmaceuticals, Inc. (Nasdaq: P...ancial results for the third quarter of fiscal yea... host a conference call and webcast to discuss the... 2009 and will review recent operating highlights....
...eives EU and US Approvals for Intravenous Formulat...l Temozolomide Sachet Presentation , , KENILWORTH...: SGP ) today announced that the European Commis...emozolomide is marketed as TEMODAL(R) in the EU an...
... Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) tod...l year 2008 financial results after the NASDAQ Glo...at same afternoon, Jack Lief, Arena,s President an.... Eastern Time (2:00 p.m. Pacific Time) to discuss...
...., March 5 Smith & Nephew Inc,s Advanced Woun...y announced the U.S. launch of its next Negative P...SYS (TM) GO, designed to address the needs of cli...wound care. The U.S. Food and Drug Administration ...
...acquisition of NMHC drives GAAP earnings per share...4 2008, up from $6.5 million in Q4, 2007, ,...C Health Solutions Corp. ("SXC" or the "Company") ... in U.S. dollars unless otherwise indicated. , "20...
...e demand for a reliable, non-invasive, efficient a...s, lifestyles is boosting interest in bone growth ...t is however still small, as clinicians have felt ... research papers to substantiate the efficacy of t...
Other Medicine News:Health News:Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results 2Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 2Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 3Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 4Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 5Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 6Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 7Health News:Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2008 Financial Results and to Host Conference Call and Webcast on Thursday, March 12, 2009 2Health News:Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2008 Financial Results and to Host Conference Call and Webcast on Thursday, March 12, 2009 3Health News:Smith & Nephew Introduces RENASYS(TM) GO, Portable NPWT for Mobile, Active Patients 2Health News:Smith & Nephew Introduces RENASYS(TM) GO, Portable NPWT for Mobile, Active Patients 3Health News:Smith & Nephew Introduces RENASYS(TM) GO, Portable NPWT for Mobile, Active Patients 4Health News:Smith & Nephew Introduces RENASYS(TM) GO, Portable NPWT for Mobile, Active Patients 5Health News:SXC Health solutions announces strong fourth quarter and year end financial results 2Health News:SXC Health solutions announces strong fourth quarter and year end financial results 3Health News:SXC Health solutions announces strong fourth quarter and year end financial results 4Health News:SXC Health solutions announces strong fourth quarter and year end financial results 5Health News:SXC Health solutions announces strong fourth quarter and year end financial results 6Health News:SXC Health solutions announces strong fourth quarter and year end financial results 7Health News:SXC Health solutions announces strong fourth quarter and year end financial results 8Health News:SXC Health solutions announces strong fourth quarter and year end financial results 9Health News:SXC Health solutions announces strong fourth quarter and year end financial results 10Health News:SXC Health solutions announces strong fourth quarter and year end financial results 11Health News:SXC Health solutions announces strong fourth quarter and year end financial results 12Health News:SXC Health solutions announces strong fourth quarter and year end financial results 13Health News:SXC Health solutions announces strong fourth quarter and year end financial results 14Health News:SXC Health solutions announces strong fourth quarter and year end financial results 15Health News:SXC Health solutions announces strong fourth quarter and year end financial results 16Health News:SXC Health solutions announces strong fourth quarter and year end financial results 17Health News:SXC Health solutions announces strong fourth quarter and year end financial results 18Health News:SXC Health solutions announces strong fourth quarter and year end financial results 19Health News:SXC Health solutions announces strong fourth quarter and year end financial results 20Health News:According to Frost & Sullivan, Mounting Clinical Evidence Underlines Benefits of Bone Growth and Spinal Fusion Stimulators 2Health News:According to Frost & Sullivan, Mounting Clinical Evidence Underlines Benefits of Bone Growth and Spinal Fusion Stimulators 3
(Date:11/20/2009)...swire/ -- ,, Reportlinker.com announces that a ...alogue. ,, Global Markets for Breast Biopsy De...164741/Global-Markets-for-Breast-Biopsy-Devices-20...p;utm_campaign=prnewswire ,, The global marke...oaded core needle market and vacuum assisted breas...
(Date:11/20/2009)...re-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX )...ef Executive Officer, and Greg Browne, Chief Finan...r Jaffray Health Care Conference in New York on We...nference session and webcast will be audio only an...ay will host a webcast of the presentation live an...
(Date:11/19/2009)...ewswire/ -- Warner Chilcott plc (Nasdaq: WCRX ) t...nced secondary offering of 20,000,000 of its ordin...share. The selling shareholders include funds aff...anking, J.P. Morgan Partners (advised by CCMP Capi...er institutional investors and members of the Comp...
Breaking Medicine Technology:Reportlinker Adds Global Markets for Breast Biopsy Devices 2009 2Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference 2Warner Chilcott Prices Secondary Equity Offering 2Warner Chilcott Prices Secondary Equity Offering 3Warner Chilcott Prices Secondary Equity Offering 4NHLBI awards 2411 million for molecular roadmap to chronic lung diseases 10289 1NHLBI awards 2411 million for molecular roadmap to chronic lung diseases 10289 2Long Term Back Pain Not Inevitable Study Finds 59075 1Long Term Back Pain Not Inevitable Study Finds 59075 2Endovenous Laser Therapy Used for Treatment of Varicose Veins 59071 1Endovenous Laser Therapy Used for Treatment of Varicose Veins 59071 2
...onference Call on Monday, April 14, at 8:30 a.m. E...m.com , CARLSBAD, Calif., April 14 Isis,Pharmace...l results from its,ongoing Phase 2 open-label exte...amilial hypercholesterolemia (FH). In FH patients ...e safety profile of the drug,continues to be encou...
...3 Researchers from the,Barbara Ann Karmanos Cance...owing that adding curcumin or resveratrol to conve...ing the growth of chemo-resistant colon cancer,cel...merican Association,for Cancer Research (AACR) Ann...om.com/cgi-bin/prnh/20071106/KARMANOSCANCERINSTITU...
Other Medicine Technology:Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 2Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 3Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 4Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 5Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 6Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells 2
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
Medicine Products: